WGU D116 ADVANCED
PHARMACOLOGY FINAL EXAM PREP
QUESTIONS AND ANSWERS 2026/2027
1. Which cytochrome P450 enzyme is responsible for the metabolism of approximately 50%
of all clinically used drugs, making it a frequent site for drug-drug interactions?
A. CYP2D6
B. CYP3A4
C. CYP1A2
D. CYP2C19
Answer: B
Conceptual Explanation: CYP3A4 is the most abundant CYP enzyme in the liver and is
involved in the metabolism of about half of all medications.
2. A patient is identified as a CYP2D6 ultra-rapid metabolizer. Which of the following
consequences is most likely when they are prescribed codeine?
A. Lack of therapeutic effect due to poor conversion to morphine
B. Increased risk of morphine toxicity and respiratory depression
,C. Prolonged half-life of the prodrug leading to accumulation
D. Reduced renal clearance of the drug metabolites
Answer: B
Conceptual Explanation: Codeine is a prodrug converted to morphine by CYP2D6. Ultra-
rapid metabolizers convert it too quickly, leading to toxic levels of morphine.
3. Which pharmacokinetic parameter describes the volume of plasma from which a drug is
completely removed per unit of time?
A. Volume of distribution (Vd)
B. Bioavailability (F)
C. Half-life (t1/2)
D. Clearance (Cl)
Answer: D
Conceptual Explanation: Clearance represents the efficiency of drug elimination from the
body, expressed as volume per time (e.g., L/hr).
4. In the context of Heart Failure with Reduced Ejection Fraction (HFrEF), which mechanism
explains the benefit of Sacubitril/Valsartan (Entresto)?
A. Direct renin inhibition and beta-receptor blockade
B. Neprilysin inhibition and Angiotensin II receptor blockade
C. Calcium channel blockade and aldosterone antagonism
, D. Inhibition of the funny current (If) in the SA node
Answer: B
Conceptual Explanation: Entresto combines an ARB (Valsartan) with a neprilysin
inhibitor (Sacubitril), which increases levels of beneficial natriuretic peptides.
5. Which of the following classes of antihyperglycemics is most likely to cause a reduction in
cardiovascular mortality and hospitalization for heart failure in patients with Type 2
Diabetes?
A. DPP-4 Inhibitors
B. Thiazolidinediones
C. Sulfonylureas
D. SGLT2 Inhibitors
Answer: D
Conceptual Explanation: SGLT2 inhibitors like empagliflozin have demonstrated
significant CV and renal benefits, particularly in preventing heart failure exacerbations.
6. What is the primary mechanism of action for the anticoagulant Dabigatran?
A. Direct Thrombin (Factor IIa) inhibition
B. Vitamin K epoxide reductase inhibition
C. Inhibition of Factor Xa
D. Potentiation of Antithrombin III
PHARMACOLOGY FINAL EXAM PREP
QUESTIONS AND ANSWERS 2026/2027
1. Which cytochrome P450 enzyme is responsible for the metabolism of approximately 50%
of all clinically used drugs, making it a frequent site for drug-drug interactions?
A. CYP2D6
B. CYP3A4
C. CYP1A2
D. CYP2C19
Answer: B
Conceptual Explanation: CYP3A4 is the most abundant CYP enzyme in the liver and is
involved in the metabolism of about half of all medications.
2. A patient is identified as a CYP2D6 ultra-rapid metabolizer. Which of the following
consequences is most likely when they are prescribed codeine?
A. Lack of therapeutic effect due to poor conversion to morphine
B. Increased risk of morphine toxicity and respiratory depression
,C. Prolonged half-life of the prodrug leading to accumulation
D. Reduced renal clearance of the drug metabolites
Answer: B
Conceptual Explanation: Codeine is a prodrug converted to morphine by CYP2D6. Ultra-
rapid metabolizers convert it too quickly, leading to toxic levels of morphine.
3. Which pharmacokinetic parameter describes the volume of plasma from which a drug is
completely removed per unit of time?
A. Volume of distribution (Vd)
B. Bioavailability (F)
C. Half-life (t1/2)
D. Clearance (Cl)
Answer: D
Conceptual Explanation: Clearance represents the efficiency of drug elimination from the
body, expressed as volume per time (e.g., L/hr).
4. In the context of Heart Failure with Reduced Ejection Fraction (HFrEF), which mechanism
explains the benefit of Sacubitril/Valsartan (Entresto)?
A. Direct renin inhibition and beta-receptor blockade
B. Neprilysin inhibition and Angiotensin II receptor blockade
C. Calcium channel blockade and aldosterone antagonism
, D. Inhibition of the funny current (If) in the SA node
Answer: B
Conceptual Explanation: Entresto combines an ARB (Valsartan) with a neprilysin
inhibitor (Sacubitril), which increases levels of beneficial natriuretic peptides.
5. Which of the following classes of antihyperglycemics is most likely to cause a reduction in
cardiovascular mortality and hospitalization for heart failure in patients with Type 2
Diabetes?
A. DPP-4 Inhibitors
B. Thiazolidinediones
C. Sulfonylureas
D. SGLT2 Inhibitors
Answer: D
Conceptual Explanation: SGLT2 inhibitors like empagliflozin have demonstrated
significant CV and renal benefits, particularly in preventing heart failure exacerbations.
6. What is the primary mechanism of action for the anticoagulant Dabigatran?
A. Direct Thrombin (Factor IIa) inhibition
B. Vitamin K epoxide reductase inhibition
C. Inhibition of Factor Xa
D. Potentiation of Antithrombin III
